CanSino Biologics Inc. (SEHK: 6185)
Health Care · Biotechnology · CN
HK$35.02
+1.10% today · -24.7% 1Y
CanSino Biologics Inc. (SEHK: 6185) operates in the Biotechnology industry within the Health Care sector. The company is valued at $2.27B and employs 1,175 people.
Over the last twelve months the share price has lost 24.7%, trading between 19.22 and 50.20.
Tweenvest scores CanSino Biologics Inc. across four factors: quality 56/100, value 49/100, growth 100/100. Its strongest factor is growth.
6185 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.27B
- Revenue (TTM)
- $181.87M
- P/E
- 184.41
- EPS
- 0.16
- Dividend yield
- —
- Beta (5Y)
- 1.13
- 52-week high
- HK$50.20
- 52-week low
- HK$19.22
- Avg volume (3M)
- —
- Shares outstanding
- 247.04M
- Employees
- 1,175
- Next earnings
- —
About CanSino Biologics Inc.
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People’s Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. In addition, it develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. Further, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CS-2023 to treat meningitis; CS-2028 for treating multivalent conjugate vaccine; CS-2032 for hingles; CS-2036 to treat polio; CS-2047 for treating tetanus; and CS-2201 DTcP for combination vaccine. The company was incorporated in 2009 and is headquartered in Tianjin, the People’s Republic of China.
- ISIN
- CNE100003F01
- Founded
- 2009
- Listed since
- Mar 28, 2019
- Exchange
- The Stock Exchange of Hong Kong Ltd.
- Currency
- HKD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Recursion Pharmaceuticals, Inc.NasdaqGS: RXRX | $2.34B | $4.36 | +10.38% |
| PharmaResearch Co., Ltd.KOSDAQ: A214450 | $2.34B | ₩302,500.00 | -1.14% |
| ADMA Biologics, Inc.NasdaqGM: ADMA | $2.32B | $10.36 | +0.29% |
| Nurix Therapeutics, Inc.NasdaqGM: NRIX | $2.32B | $22.35 | -2.78% |
| Shenzhen Kangtai Biological Products Co., Ltd.SZSE: 300601 | $2.24B | CN¥13.44 | -1.03% |
| Immunome, Inc.NasdaqCM: IMNM | $2.22B | $19.55 | -6.46% |
| Aurinia Pharmaceuticals Inc.NasdaqGM: AUPH | $2.22B | $16.65 | +2.65% |
| Hyperliquid Strategies Inc.NasdaqCM: PURR | $2.20B | $11.11 | -1.68% |
Figures last refreshed Oct 11, 2026.